<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194242</url>
  </required_header>
  <id_info>
    <org_study_id>HEC96719-P-01/CRC-C1931</org_study_id>
    <nct_id>NCT04194242</nct_id>
  </id_info>
  <brief_title>The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects</brief_title>
  <official_title>A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Access the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HEC96719 Tablets in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a safety, tolerability, and pharmacokinetics phase Ⅰstudy of HEC96719, in
      healthy subjects.This study is the healthy adult subjects single ascending-dose research
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and tolerability of escalating single oral doses of
      HEC96719, and characterize the single-dose pharmacokinetics (PK) of HEC96719. Participants
      will receive either HEC96719 or HEC96719 placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2020</start_date>
  <completion_date type="Anticipated">October 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events of the single ascending-dose</measure>
    <time_frame>From the baseline to day7</time_frame>
    <description>To assess the safe and tolerability of the single ascending-dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>At pre-defined intervals from Days 1-2</time_frame>
    <description>Maximum Plasma Concentration(Cmax)of HEC96719 in single ascending dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>At pre-defined intervals from Days 1-2</time_frame>
    <description>Area Under the Curve(AUC) of HEC96719 in single ascending dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>At pre-defined intervals from Days 1-2</time_frame>
    <description>Maximum Peak Time(Tmax) of HEC96719 in single ascending dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>At pre-defined intervals from Days 1-2</time_frame>
    <description>Terminal elimination half-life(T1/2) of HEC96719 in single ascending dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>HEC96719 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Including 7 dose groups(0.1-、0.2、0.5-、1-、2-、3-、4 mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240 mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Including 7 dose groups(0.1-、0.2、0.5-、1-、2-、3-、4 mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC96719 tablets</intervention_name>
    <description>0.1-、0.2-、0.5-、1-、2-、3-、4 mg HEC96719 tablet in day1</description>
    <arm_group_label>HEC96719 tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>0.1-、0.2-、0.5-、1-、2-、3-、4 mg Placebo tablet in day1</description>
    <arm_group_label>placebo tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to participate in the study, able to understand and sign the informed consent,
             and able to complete the the study in accordance with the requirements of the study.

          -  Female subjects who are not pregnant or lactating and male subjects whose female
             partners are fertile shall voluntarily take effective contraceptive measures from the
             date of signing the informed consent form to 3 months after the medication.

          -  When signing the informed consent, 18 years old ≤the age≤45 years old(including the
             critical value), gender is not limited.

          -  Male body weight ≥50kg, female body weight ≥45kg, and body mass index (BMI) in the
             range of 18-28 kg/m2 (including the critical value).

          -  No clinical significance of vital signs, physical examination, laboratory examination,
             electrocardiogram, ultrasound abdomen and chest X-ray (posterior and anterior)
             results.

        Exclusion Criteria:

          -  Positive for Viral hepatitis (including hepatitis B and C), HIV and syphilis.

          -  Those who are known to have allergy history or allergy constitution to the test
             preparation and any of its components or related preparations.

          -  Intemperant or regular drinkers within 3 months prior to the study, i.e., those who
             consumed more than 21 units of alcohol per week (1 unit =360mL beer or 45mL spirit
             with 40% alcohol or 150mL wine), or those who were positive on the alcohol breath
             test.

          -  Those who had a blood donation or blood loss of &gt;400mL within one month before taking
             the study drug.

          -  Those who have participated in clinical trials of other drugs within 3 months before
             randomization.

          -  Subjects considered by the investigator to have other factors unsuitable for
             participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>yanmei Liu, Doctor</last_name>
    <phone>021-54030254</phone>
    <email>ymliu@shxh-centerlab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Shanghai xuhui district central hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yanmei Liu, Doctor</last_name>
      <phone>021-54030254</phone>
      <email>ymliu@shxh-centerlab.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

